BRPI0113470B8 - composto de ligação amilóide, composição farmacêutica e métodos de síntese de composto, de detecção in vivo de depósitos amilóides num indivíduo e em tecido humano ou animal, de quantificação de depósito amilóide em tecido de biópsia ou postmortem e de distinção de um cérebro de doença de alzheimer de um cérebro normal - Google Patents

composto de ligação amilóide, composição farmacêutica e métodos de síntese de composto, de detecção in vivo de depósitos amilóides num indivíduo e em tecido humano ou animal, de quantificação de depósito amilóide em tecido de biópsia ou postmortem e de distinção de um cérebro de doença de alzheimer de um cérebro normal

Info

Publication number
BRPI0113470B8
BRPI0113470B8 BRPI0113470A BRPI0113470B8 BR PI0113470 B8 BRPI0113470 B8 BR PI0113470B8 BR PI0113470 A BRPI0113470 A BR PI0113470A BR PI0113470 B8 BRPI0113470 B8 BR PI0113470B8
Authority
BR
Brazil
Prior art keywords
amyloid
brain
tissue
methods
biopsy
Prior art date
Application number
Other languages
English (en)
Portuguese (pt)
Inventor
A Mathis Chester Jr
E Klunk William
Wang Yanming
Original Assignee
Univ Pittsburgh
Univ Pittsburgh Commonwealth Sys Higher Education
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Pittsburgh, Univ Pittsburgh Commonwealth Sys Higher Education filed Critical Univ Pittsburgh
Publication of BR0113470A publication Critical patent/BR0113470A/pt
Publication of BRPI0113470B1 publication Critical patent/BRPI0113470B1/pt
Publication of BRPI0113470B8 publication Critical patent/BRPI0113470B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/64—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/64—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2
    • C07D277/66—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2 with aromatic rings or ring systems directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicinal Preparation (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
  • Nuclear Medicine (AREA)
BR0113470-1 2000-08-24 2001-08-24 composto de ligação amilóide, composição farmacêutica e métodos de síntese de composto, de detecção in vivo de depósitos amilóides num indivíduo e em tecido humano ou animal, de quantificação de depósito amilóide em tecido de biópsia ou postmortem e de distinção de um cérebro de doença de alzheimer de um cérebro normal BRPI0113470B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US22760100P 2000-08-24 2000-08-24
US60/227,601 2000-08-24
PCT/US2001/026427 WO2002016333A2 (en) 2000-08-24 2001-08-24 Thioflavin derivatives and their use in diagnosis and theraphy of alzheimer's disease

Publications (3)

Publication Number Publication Date
BR0113470A BR0113470A (pt) 2003-12-30
BRPI0113470B1 BRPI0113470B1 (pt) 2019-04-16
BRPI0113470B8 true BRPI0113470B8 (pt) 2021-05-25

Family

ID=22853739

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0113470-1 BRPI0113470B8 (pt) 2000-08-24 2001-08-24 composto de ligação amilóide, composição farmacêutica e métodos de síntese de composto, de detecção in vivo de depósitos amilóides num indivíduo e em tecido humano ou animal, de quantificação de depósito amilóide em tecido de biópsia ou postmortem e de distinção de um cérebro de doença de alzheimer de um cérebro normal

Country Status (18)

Country Link
US (5) US20020133019A1 (enExample)
EP (2) EP2264018B1 (enExample)
JP (2) JP5022554B2 (enExample)
CN (1) CN1285582C (enExample)
AU (3) AU2001286702B2 (enExample)
BR (1) BRPI0113470B8 (enExample)
CA (1) CA2419420C (enExample)
CY (1) CY1113311T1 (enExample)
DK (2) DK2264018T3 (enExample)
ES (2) ES2536449T3 (enExample)
HU (2) HU230581B1 (enExample)
LT (1) LTC1334091I2 (enExample)
NO (1) NO330176B1 (enExample)
PL (1) PL215711B1 (enExample)
PT (2) PT2264018E (enExample)
RU (1) RU2324686C2 (enExample)
SI (1) SI1334091T1 (enExample)
WO (1) WO2002016333A2 (enExample)

Families Citing this family (115)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6689753B1 (en) * 1999-11-05 2004-02-10 Axonyx, Inc. β sheet breaker peptide analogs that inhibit β pleated sheet formation in amyloid β-peptide
US20030138374A1 (en) * 2000-03-22 2003-07-24 Yukitsuda Kudo Image diagnosis probe based on substituted azobenzene or analogue thereof for disease attributable to amyloid accumulation and composition for image diagnosis containing the same
US7297326B2 (en) * 2000-08-21 2007-11-20 The General Hospital Corporation Ocular diagnosis of Alzheimer's disease
AU2001285170B2 (en) 2000-08-21 2006-10-26 The Brigham And Women's Hospital, Inc. Methods for diagnosing a neurodegenerative condition
US7270800B2 (en) 2000-08-24 2007-09-18 University Of Pittsburgh Thioflavin derivatives for use in antemortem diagnosis of Alzheimer's disease and in vivo imaging and prevention of amyloid deposition
WO2002016333A2 (en) 2000-08-24 2002-02-28 University Of Pittsburgh Thioflavin derivatives and their use in diagnosis and theraphy of alzheimer's disease
WO2002064084A2 (en) * 2000-11-02 2002-08-22 Cornell Research Foundation, Inc. In vivo multiphoton diagnostic detection and imaging of a neurodegenerative disease
EP1345914A1 (en) * 2000-12-22 2003-09-24 AstraZeneca AB Therapeutic compounds
GB0106953D0 (en) 2001-03-20 2001-05-09 Univ Aberdeen Neufofibrillary labels
EP1478631A1 (en) * 2001-11-28 2004-11-24 AstraZeneca AB Therapeutic compounds
US6774248B2 (en) 2001-12-18 2004-08-10 Wyeth Substituted 2-phenyl benzofurans as estrogenic agents
EP1820806A1 (en) * 2006-02-16 2007-08-22 Crossbeta Biosciences B.V. Affinity regions
AU2003239508A1 (en) 2002-05-21 2003-12-12 Bristol-Myers Squibb Company Indole compounds useful as impdh inhibitors
WO2003106439A1 (ja) * 2002-06-12 2003-12-24 株式会社ビーエフ研究所 アミロイド蓄積性疾患の画像診断プローブ化合物、老人斑／びまん性老人斑染色用化合物、ならびにアミロイド蓄積性疾患の治療薬
EP1380290A1 (en) * 2002-07-09 2004-01-14 Universitair Medisch Centrum Utrecht Cross-beta structure pathway and its therapeutic relevance
US20070003552A1 (en) * 2002-07-09 2007-01-04 Gebbink Martijn F B Cross-beta structure comprising amyloid binding proteins and methods for detection of the cross-beta structure, for modulating cross-beta structures fibril formation and for modulating cross-beta structure-mediated toxicity and method for interfering with blood coagulation
JPWO2004035522A1 (ja) * 2002-08-30 2006-02-16 株式会社 ビーエフ研究所 プリオン蛋白蓄積性疾患の診断プローブおよび治療薬ならびにプリオン蛋白の染色剤
EP1587821B9 (en) 2002-12-19 2025-07-02 The Scripps Research Institute Compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding
GB0229686D0 (en) 2002-12-20 2003-01-29 Amersham Plc Solid-phase fluorination of benzothiazoles
CA2438032C (en) * 2003-03-14 2013-05-07 University Of Pittsburgh Benzothiazole derivative compounds, compositions and uses
PL1611115T3 (pl) * 2003-03-14 2013-01-31 Univ Pittsburgh Commonwealth Sys Higher Education Związki pochodne benzotiazolu, kompozycje i zastosowania
GB0307855D0 (en) * 2003-04-04 2003-05-14 Novartis Ag Organic compounds
EP1631561B1 (en) 2003-05-07 2010-08-18 General Electric Company Compositions and methods for non-invasive imaging of soluble beta-amyloid
US20040223912A1 (en) * 2003-05-07 2004-11-11 Montalto Michael Christopher Compositions and methods for non-invasive imaging of soluble beta-amyloid
AU2003304416A1 (en) * 2003-08-13 2005-03-07 Bf Research Institute, Inc. Probe for disease with amyloid deposit, amyloid-staining agent, remedy and preventive for disease with amyloid deposit and diagnostic probe and staining agent for neurofibril change
MXPA06001742A (es) * 2003-08-13 2006-08-11 Bf Res Inst Inc Sondas para enfermedades en las cuales se acumula amiloide, agentes para tincion del amiloide, farmacos para tratamiento y profilaxis de enfermedades con amiloide acumulado, y sondas para diagnostico de ovillos neurofibrilares y agentes para tincion
US8236282B2 (en) 2003-08-22 2012-08-07 University of Pittsburgh—of the Commonwealth System of Higher Education Benzothiazole derivative compounds, compositions and uses
WO2005042461A1 (ja) * 2003-10-30 2005-05-12 Dojindo Laboratories アミロイド親和性化合物
JP4910695B2 (ja) * 2004-02-25 2012-04-04 アステラス製薬株式会社 血栓造影剤
JP5039541B2 (ja) 2004-04-27 2012-10-03 ワイス・エルエルシー プロゲステロン受容体調節剤の精製
GB0410448D0 (en) 2004-05-11 2004-06-16 Hammersmith Imanet Ltd Purification methods
WO2005118511A2 (en) 2004-05-20 2005-12-15 The Scripps Research Institute Compounds, compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding
US8147798B2 (en) * 2004-07-02 2012-04-03 University of Pittsburgh—of the Commonwealth System of Higher Education Amyloid imaging as a surrogate marker for efficacy of anti-amyloid therapies
CN101060865B (zh) * 2004-07-02 2011-10-05 匹兹堡大学高等教育联邦体系 诊断淀粉样蛋白沉积相关疾病的前驱形式的方法
US7781478B2 (en) 2004-07-14 2010-08-24 Ptc Therapeutics, Inc. Methods for treating hepatitis C
US7868037B2 (en) 2004-07-14 2011-01-11 Ptc Therapeutics, Inc. Methods for treating hepatitis C
CA2573185A1 (en) 2004-07-14 2006-02-23 Ptc Therapeutics, Inc. Methods for treating hepatitis c
US7772271B2 (en) 2004-07-14 2010-08-10 Ptc Therapeutics, Inc. Methods for treating hepatitis C
CA2573819A1 (en) * 2004-07-15 2006-02-23 The General Hospital Corporation Heterocyclic dye compounds for in vivo imaging and diagnosis of alzheimer's disease
JP2008507518A (ja) 2004-07-22 2008-03-13 ピーティーシー セラピューティクス，インコーポレーテッド Ｃ型肝炎を治療するためのチエノピリジン
CA2615020A1 (en) * 2005-07-13 2007-01-18 Crossbeta Biosciences B.V. Adjuvation through cross-.beta. structure
US20070015133A1 (en) * 2005-07-13 2007-01-18 Umc Utrecht Holding B.V. Method for detecting and/or removing protein and/or peptide comprising a cross-beta structure from an aqueous solution comprising a protein
EP1910844B1 (en) 2005-07-13 2012-04-18 Crossbeta Biosciences B.V. Cross-beta structure binding compounds
US8114832B2 (en) * 2005-07-13 2012-02-14 Crossbeta Biosciences B.V. Method for detecting and/or removing a protein comprising a cross-beta structure from a pharmaceutical composition
CN101355940B (zh) * 2005-09-16 2013-03-27 匹兹堡大学高等教育联邦体系 用于检测具有至少一种促淀粉样变蛋白的淀粉样沉积物的体内或体外方法
KR100778888B1 (ko) * 2005-11-29 2007-11-28 재단법인서울대학교산학협력재단 베타아밀로이드 펩타이드 플라크의 영상화를 위한벤질리덴아닐린 계열의 유도체 및 그의 방사성 동위원소표지화합물
US8022075B2 (en) 2005-11-30 2011-09-20 Fujifilm Ri Pharma Co., Ltd. Diagnostic and remedy for disease caused by amyloid aggregation and/or deposition
JP2009519239A (ja) * 2005-12-01 2009-05-14 ユニバーシティ オブ ピッツバーグ オブ ザ コモンウェルス システム オブ ハイヤー エデュケーション アミロイド生成性タンパク質の造影剤としての同位体標識ベンゾチアゾール化合物
WO2007075595A2 (en) * 2005-12-20 2007-07-05 Vertex Pharmacueticals Incorporated Biofilm assay
US7781187B2 (en) * 2005-12-30 2010-08-24 Corning Incorporated Fluorescent dyes
TW200736252A (en) 2006-01-27 2007-10-01 Astrazeneca Ab Novel heteroaryl substituted benzothiazoles
KR101426093B1 (ko) 2006-02-10 2014-08-01 서미트 코포레이션 피엘씨 뒤시엔느 근이영양증의 치료
WO2007111179A1 (ja) * 2006-03-28 2007-10-04 Shiga University Of Medical Science 神経難病の画像診断薬
TW200803903A (en) 2006-04-28 2008-01-16 Nihon Mediphysics Co Ltd Novel compound having affinity to amyloid
EP2023919A4 (en) * 2006-05-08 2010-12-22 Molecular Neuroimaging Llc COMPOUNDS AND AMYLOID PROBES FOR THERAPY AND IMAGING USES
WO2007135890A1 (ja) 2006-05-19 2007-11-29 Nihon Medi-Physics Co., Ltd. 新規アミロイド親和性化合物
TW200813035A (en) 2006-06-19 2008-03-16 Astrazeneca Ab Novel heteroaryl substituted benzoxazoles
EP2042501B1 (en) 2006-06-21 2017-04-12 Nihon Medi-Physics Co., Ltd. Compound having affinity for amyloid
EP2059491A1 (en) * 2006-08-03 2009-05-20 Hammersmith Imanet Limited Method for the purification of radiolabelled compounds
AU2007326707A1 (en) 2006-11-30 2008-06-05 Nihon Medi-Physics Co., Ltd. Novel compound having affinity for amyloid
CN101668560A (zh) * 2006-12-07 2010-03-10 宾夕法尼亚大学理事会 乙炔衍生物及它们在结合和显像淀粉样斑块中的应用
AU2008211786B2 (en) * 2007-01-30 2014-07-03 Ge Healthcare Limited Tools for aiding in the diagnosis of neurodegenerative diseases
JP5258583B2 (ja) 2007-02-13 2013-08-07 日本メジフィジックス株式会社 放射性画像診断剤の製造方法
TW200901998A (en) 2007-03-06 2009-01-16 Astrazeneca Ab Novel 2-heteroaryl substituted benzothiophenes and benzofuranes
CN101293878B (zh) * 2007-04-25 2010-12-15 中国科学院上海应用物理研究所 苯并噻唑苯胺类化合物及其制备方法和应用
PE20090510A1 (es) 2007-08-03 2009-05-22 Summit Corp Plc Combinaciones de drogas para el tratamiento de la distrofia muscular de duchenne
DK2182988T3 (da) * 2007-08-30 2014-05-26 Ge Healthcare Ltd Radiofarmaceutisk præparat
TW200918102A (en) * 2007-10-24 2009-05-01 Nihon Mediphysics Co Ltd Novel compound having affinity for amyloid
CN101903383A (zh) 2007-10-26 2010-12-01 日本医事物理股份有限公司 对淀粉样蛋白具有亲和性的新化合物
CA2704139A1 (en) 2007-10-30 2009-05-07 Nihon Medi-Physics Co., Ltd. Utilization of novel compounds with amyloid affinity and method of producing the same
EP2216051A1 (en) * 2007-10-30 2010-08-11 Nihon Medi-Physics Co., Ltd. Use of novel compound having affinity for amyloid, and process for production of the same
US20090123373A1 (en) * 2007-11-05 2009-05-14 Yanming Wang Amyloid-imaging agents
EP2058001A1 (en) * 2007-11-08 2009-05-13 Crossbeta Biosciences B.V. Enhancement of immunogenicity of antigens
EP2058000A1 (en) * 2007-11-08 2009-05-13 Crossbeta Biosciences B.V. Immunogenic compositions capable of activating T cells
CN102047061A (zh) * 2008-05-30 2011-05-04 福斯特韦勒能源股份公司 通过氧化燃料燃烧发电的方法和系统
US20110076230A1 (en) * 2008-05-30 2011-03-31 Barrow James C Novel Substituted Indoles
CA2725940A1 (en) 2008-05-30 2009-12-23 Merck Sharp & Dohme Corp. Novel substituted azabenzoxazoles
EP2684873B1 (en) * 2008-06-09 2019-01-16 Ludwig-Maximilians-Universität München Drugs for inhibiting aggregation of proteins involved in diseases linked to protein aggregation and/or neurodegenerative diseases
US20100099609A1 (en) * 2008-07-28 2010-04-22 Buck Institute For Age Research eAPP AND DERIVATIVES FOR TREATMENT OF ALZHEIMER'S DISEASE
EP2910945B1 (en) 2008-09-30 2018-07-18 Case Western Reserve University Molecular probes for imaging of myelin
EP2365974B1 (en) * 2008-11-06 2013-12-25 SNU R&DB Foundation Fluorinated benzothiazole derivatives, preparation method thereof and imaging agent for diagnosing altzheimer's disease using the same
US20100129290A1 (en) * 2008-11-26 2010-05-27 I.S.T. Corporation Smart contrast agent and detection method for detecting transition metal ions
CN101598703B (zh) * 2009-07-03 2012-08-22 中国人民解放军第三军医大学第一附属医院 dGTpase蛋白在制备用于鉴别诊断唐氏胎儿药物中的应用
FR2948685A1 (fr) * 2009-07-30 2011-02-04 Biomerieux Sa Nouveaux substrats
US20110081428A1 (en) * 2009-09-16 2011-04-07 The Buck Institute For Age Research Use of thioflavin-like compounds to increase life span and/or health span
DE102010045797A1 (de) 2010-09-20 2012-03-22 Klinikum Darmstadt Gmbh Verbindungen für die Diagnostik neurodegenerativer Erkrankungen am Riechepithel
EP2619590A2 (de) 2010-09-20 2013-07-31 Technische Universität Darmstadt Verbindungen für die diagnostik neurodegenerativer erkrankungen an der retina
KR20140040722A (ko) 2011-05-20 2014-04-03 니혼 메디피직스 가부시키가이샤 신규 아밀로이드 친화성 화합물
ES2619830T3 (es) 2011-06-24 2017-06-27 Nihon Medi-Physics Co., Ltd. Nuevo compuesto con afinidad por amiloide
WO2013027694A1 (ja) * 2011-08-24 2013-02-28 国立大学法人京都大学 コンフォメーション病診断用分子イメージングプローブ
BR112014005810A2 (pt) 2011-09-16 2017-03-28 Pfizer formas sólidas de um inibidor da dissociação de transtirretina
CN102526765B (zh) * 2011-12-31 2014-07-30 郑州泰基鸿诺药物科技有限公司 一种Aβ斑块显像剂及其制备方法
KR20130111082A (ko) * 2012-03-30 2013-10-10 한미약품 주식회사 베타-아밀로이드 피브릴 형성 저해 효능을 갖는 아미노스티릴벤조퓨란 화합물 및 이를 함유하는 약학 조성물
EP2890700B1 (de) * 2012-08-28 2017-12-13 Eberhard Karls Universität Tübingen Medizinische Fakultät Halogenierte benzoxazine und ihre verwendung
WO2014032732A1 (de) 2012-08-28 2014-03-06 Eberhard Karls Universität Tübingen Medizinische Fakultät Halogenierte benzoxazine und ihre verwendung
US10604516B2 (en) 2012-12-21 2020-03-31 National Institutes For Quantum And Radiological Science And Technology Compounds for imaging tau proteins that accumulate in the brain
US9246108B2 (en) 2012-12-28 2016-01-26 Dow Global Technologies Llc Quinoline-benzoxazole derived compounds for electronic films and devices
WO2014127365A1 (en) 2013-02-15 2014-08-21 Case Western Reserve University Psma ligands and uses thereof
JP6182668B2 (ja) 2013-09-26 2017-08-16 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 画像化ツールとしてのイミダゾ［１，２−ａ］ピリジン−７−アミン
WO2015051188A1 (en) 2013-10-02 2015-04-09 Washington University Heterocyclic molecules for biomedical imaging and therapeutic applications
EP3135280B1 (en) 2014-04-24 2023-09-20 Omoidesouzou Co. Ltd. Tranilast for the treatment of cutaneous amyloidosis
CN104059028B (zh) * 2014-06-06 2020-10-16 北京智博高科生物技术有限公司 与Aβ斑块具有亲和力的含手性侧链取代的氟代2-芳基苯并杂环化合物、其制备方法及应用
JP6498412B2 (ja) * 2014-10-17 2019-04-10 国立大学法人群馬大学 新規チオフラビンｔ誘導体及びその利用
US9842938B2 (en) 2015-03-24 2017-12-12 Semiconductor Energy Laboratory Co., Ltd. Semiconductor device and display device including semiconductor device
US10765763B2 (en) 2016-03-09 2020-09-08 Case Western Reserve University Radioligands for myelin
SG11201807778YA (en) * 2016-03-11 2018-10-30 Ac Immune Sa Bicyclic compounds for diagnosis and therapy
US10675365B2 (en) 2016-09-29 2020-06-09 Korea Atomic Energy Research Institute Curcumin derivative, method for producing same, and photo-acoustic imaging agent comprising same for detecting beta-amyloid plaque
MY208662A (en) 2018-04-18 2025-05-22 Constellation Pharmaceuticals Inc Modulators of methyl modifying enzymes, compositions and uses thereof
US11167283B2 (en) 2018-05-04 2021-11-09 University Of South Carolina Dot blot box and use thereof
KR102572014B1 (ko) 2018-05-09 2023-08-29 아프리노이아 테라퓨틱스 리미티드 헤테로아릴 화합물 및 이의 용도
WO2019226491A1 (en) 2018-05-21 2019-11-28 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
SMT202500291T1 (it) * 2019-01-31 2025-09-12 Spinogenix Inc Forme solide di un promotore di spinogenesi
WO2021016414A1 (en) 2019-07-24 2021-01-28 Constellation Pharmaceuticals, Inc. Crystalline forms of 7-chloro-2-(4-(3-methoxyazetidin-1-yl)cyclohexyl)-2,4-dimethyl-n-((6-methyl-4-(methylthio)-2-oxo-1,2-dihydropyridin-3-yl)methyl)benzo[d][1,3]dioxole-5-carboxamide
AU2020383593A1 (en) 2019-11-13 2022-06-09 Aprinoia Therapeutics Limited Compounds for degrading Tau protein aggregates and uses thereof
KR102426160B1 (ko) 2020-07-13 2022-07-29 (주)바이오액츠 알츠하이머 진단용 신규 형광화합물 및 이의 제조방법

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA241942A (en) 1924-08-05 Martinetto Vittorio Asynchronous machine
US2715629A (en) * 1952-07-16 1955-08-16 Du Pont Sulfonic acid derivatives of 2-(4'-dialkylaminophenyl)-benzothiazole
NL242547A (enExample) * 1958-08-22
DE3148291A1 (de) 1981-12-05 1983-06-09 Basf Ag, 6700 Ludwigshafen Harnstoffderivate, verfahren zu ihrer herstellung und ihre verwendung zur bekaempfung unerwuenschten pflanzenwuchses
DE3307364A1 (de) * 1983-03-02 1984-09-06 Hoechst Ag, 6230 Frankfurt Zweikomponenten-diazontypiematerial
US4666829A (en) 1985-05-15 1987-05-19 University Of California Polypeptide marker for Alzheimer's disease and its use for diagnosis
AU620327B2 (en) * 1987-04-08 1992-02-20 Salutar, Inc. Amyloidosis and alzheimer's disease diagnostic assay and reagents therefor
US4933156A (en) * 1987-04-08 1990-06-12 Salutar, Inc. Amyloidosis and Alzheimer's disease diagnostic assay and reagents therefor
CA1339014C (en) 1987-10-08 1997-03-25 Ronald E. Majocha Antibodies to a4 amyloid peptide
US5231000A (en) 1987-10-08 1993-07-27 The Mclean Hospital Antibodies to A4 amyloid peptide
US5297562A (en) 1991-04-01 1994-03-29 President And Fellows Of Harvard College Method for detecting and treating Alzheimer's disease
US5434050A (en) 1991-08-13 1995-07-18 Regents Of The University Of Minnesota Labelled β-amyloid peptide and methods of screening for Alzheimer's disease
GB9317949D0 (en) * 1993-08-28 1993-10-13 Stevens Malcolm F G Benzothiazole compounds
CA2182731A1 (en) 1994-02-03 1995-08-10 Michael P. Vitek Compositions and methods for advanced glycosylation endproduct-mediated modulation of amyloidosis
US6168776B1 (en) 1994-07-19 2001-01-02 University Of Pittsburgh Alkyl, alkenyl and alkynyl Chrysamine G derivatives for the antemortem diagnosis of Alzheimer's disease and in vivo imaging and prevention of amyloid deposition
US6417178B1 (en) * 1994-07-19 2002-07-09 University Of Pittsburgh Amyloid binding nitrogen-linked compounds for the antemortem diagnosis of alzheimer's disease, in vivo imaging and prevention of amyloid deposits
GB9503946D0 (en) * 1995-02-28 1995-04-19 Cancer Res Campaign Tech Benzazole compounds
KR19990008328A (ko) 1995-05-01 1999-01-25 제롬 코크란 알쯔하이머 질환의 생전 진단 및 생체내 영상화 및 아밀로이드침착 예방을 위한 아조 화합물
AU1529297A (en) 1996-01-24 1997-08-20 Warner-Lambert Company Method of imaging amyloid deposits
JP2001510450A (ja) * 1996-10-23 2001-07-31 ザイモジェネティクス，インコーポレイテッド 骨欠損状態を処置するための組成物および方法
ID22275A (id) 1996-11-22 1999-09-23 Elan Pharm Inc Komposisi farmasi yang terdiri dari derivat asam amino n-(aril atau heteroaril) dan metode untuk menghambat pelepasan b-amiloid peptida dan atau sintesisnya dengan menggunakan senyawa tersebut
WO1999026919A1 (en) * 1997-11-20 1999-06-03 Teijin Limited Biphenylamidine derivatives
WO2000002004A2 (en) 1998-06-30 2000-01-13 Kevin Mcclung Controlled-penetration projectile
JP3820037B2 (ja) * 1998-11-05 2006-09-13 三井化学株式会社 光記録媒体
GB9919673D0 (en) * 1999-08-20 1999-10-20 Cancer Res Campaign Tech 2-Arlybenzazole compounds
US7270800B2 (en) * 2000-08-24 2007-09-18 University Of Pittsburgh Thioflavin derivatives for use in antemortem diagnosis of Alzheimer's disease and in vivo imaging and prevention of amyloid deposition
WO2002016333A2 (en) 2000-08-24 2002-02-28 University Of Pittsburgh Thioflavin derivatives and their use in diagnosis and theraphy of alzheimer's disease
EP1345914A1 (en) 2000-12-22 2003-09-24 AstraZeneca AB Therapeutic compounds
KR20040058111A (ko) * 2001-04-23 2004-07-03 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 아밀로이드 플라크 응집 억제제 및 진단 영상화제
GB0229686D0 (en) 2002-12-20 2003-01-29 Amersham Plc Solid-phase fluorination of benzothiazoles
PL1611115T3 (pl) * 2003-03-14 2013-01-31 Univ Pittsburgh Commonwealth Sys Higher Education Związki pochodne benzotiazolu, kompozycje i zastosowania
US8236282B2 (en) * 2003-08-22 2012-08-07 University of Pittsburgh—of the Commonwealth System of Higher Education Benzothiazole derivative compounds, compositions and uses
US8147798B2 (en) * 2004-07-02 2012-04-03 University of Pittsburgh—of the Commonwealth System of Higher Education Amyloid imaging as a surrogate marker for efficacy of anti-amyloid therapies
EP1945622B1 (en) * 2005-10-11 2011-12-28 University of Pittsburgh - Of the Commonwealth System of Higher Education Isotopically-labeled benzofuran compounds as imagingagents for amyloidogenic proteins

Also Published As

Publication number Publication date
PT1334091E (pt) 2013-01-07
DK2264018T3 (en) 2015-05-11
WO2002016333A3 (en) 2002-05-30
EP1334091A2 (en) 2003-08-13
US9833458B2 (en) 2017-12-05
US20080154042A1 (en) 2008-06-26
US20020133019A1 (en) 2002-09-19
LTC1334091I2 (lt) 2018-05-25
US20120095235A1 (en) 2012-04-19
NO20030860D0 (no) 2003-02-24
HU230581B1 (hu) 2017-01-30
CA2419420A1 (en) 2002-02-28
JP2004506723A (ja) 2004-03-04
ES2395721T3 (es) 2013-02-14
EP2264018B1 (en) 2015-02-11
HK1058041A1 (en) 2004-04-30
BRPI0113470B1 (pt) 2019-04-16
EP2264018A3 (en) 2012-04-25
CN1535268A (zh) 2004-10-06
RU2324686C2 (ru) 2008-05-20
EP2264018A2 (en) 2010-12-22
JP5022554B2 (ja) 2012-09-12
HK1146725A1 (en) 2011-07-08
US20150190400A1 (en) 2015-07-09
AU2008202626B9 (en) 2010-02-11
EP1334091B1 (en) 2012-09-19
AU2008202626B2 (en) 2010-02-04
SI1334091T1 (sl) 2013-01-31
NO20030860L (no) 2003-04-24
BR0113470A (pt) 2003-12-30
AU8670201A (en) 2002-03-04
HUP0302956A3 (en) 2006-05-29
HUP1500560A2 (en) 2003-12-29
CY1113311T1 (el) 2016-04-13
JP2012102106A (ja) 2012-05-31
US7351401B2 (en) 2008-04-01
US20050043377A1 (en) 2005-02-24
HU230375B1 (hu) 2016-03-29
PL360550A1 (en) 2004-09-06
CN1285582C (zh) 2006-11-22
PL215711B1 (pl) 2014-01-31
AU2008202626A1 (en) 2008-07-03
DK1334091T3 (da) 2012-10-15
AU2001286702B2 (en) 2008-03-13
PT2264018E (pt) 2015-06-03
NO330176B1 (no) 2011-02-28
ES2536449T3 (es) 2015-05-25
HUP0302956A2 (hu) 2003-12-29
WO2002016333A2 (en) 2002-02-28
LTPA2015001I1 (lt) 2015-02-25
CA2419420C (en) 2011-08-02

Similar Documents

Publication Publication Date Title
BRPI0113470B8 (pt) composto de ligação amilóide, composição farmacêutica e métodos de síntese de composto, de detecção in vivo de depósitos amilóides num indivíduo e em tecido humano ou animal, de quantificação de depósito amilóide em tecido de biópsia ou postmortem e de distinção de um cérebro de doença de alzheimer de um cérebro normal
US8168800B2 (en) Aβ-binding small molecules
ES2379987T3 (es) Compuestos de benzofurano marcados isotópicamente como radiotrazadores para proteínas amiloidógenas
Mann Pyramidal nerve cell loss in Alzheimer's disease
RU2498988C2 (ru) Ингибиторы активности протеинтирозинкиназы
UA95267C2 (en) Heteroaryl substituted benzothiazoles
BR9812776A (pt) Composto para o dignóstico antemortem de doença de alzheimer e diagnóstico por imagens in vivo e prevenção de deposição amilóide
WO2009155017A3 (en) Novel substituted azabenzoxazoles
BR112012026249A2 (pt) composto, formulação radiofarmacêutica, composição farmacêutica, uso do composto, mistura, métodos de coletar dados para o diagnóstico de uma doença ou condição associadascom amiloide, de determinar a extensão de carga amiloidogênica de placas em um tecido e/ou um fluido corporal, de coletar dados para determinar uma predisposição a uma doença ou condição associadas com amiloide em um paciente, de coletar dados para monitorar a doença residual mínima em um paciente seguindo o tratamento com um anticorpo ou uma composição de vacina, de coletar dados para predizer capacidade de reação de um paciente sendo tratado com um anticorpo ou uma composição de vacina, e, kit de teste.
BRPI0408274A (pt) compostos de ligação de amilóide, composição farmacêutica e método de detecção de depósito de amilóide in vivo
JP5605659B2 (ja) 細胞保護剤
BRPI0619251A2 (pt) compostos de ligação amilóide, composição farmacêutica e métodos de detecção de depósito(s) amilóides (s) in vivo, in vitro, de distinção de cérebro da doença de alzheimer de cérebro normal, de detecção e medição de depósitos amilóides em tecido de biópsia ou post-mortem humano ou animal, de ligação seletiva de composto de ligação amilóide, de identificação de paciente como prodrômico para doença associada com a deposição amilóide e de determinação da eficácia da terapia no tratamento da amiloidose
US20210252023A1 (en) Methods and compositions for treating and/or preventing the progression and/or onset of age-related neurodegeneration
RU2002111355A (ru) Производные 5бета-сапогенина и псевдосапогенина и их применение при лечении деменции
JP2008535805A (ja) 末梢神経毒症状を処置するためのａｄｎｆポリペプチドの使用
GB0322756D0 (en) Methods of chemical synthesis
BRPI0808503B8 (pt) composto, uso de um composto, e, composição farmacêutica
EA201100267A1 (ru) Новые бензофураны, подходящие в качестве предшественников соединений, которые являются полезными для визуализации амилоидных отложений
BRPI0808090A2 (pt) Composto, composição farmacêutica, e, método in vivo para medir depósitos de amilóide em um paciente
US20190284123A1 (en) Bridged bicyclic compounds and their derivatives as neuroprotrctive agents and methods of use thereof
Pan et al. Salidroside ameliorates orthopedic surgery-induced cognitive dysfunction by activating adenosine 5′-monophosphate-activated protein kinase signaling in mice
WO2004080285A3 (en) Amyloid plaque as a target for therapeutics that function by blocking or disrupting chitin synthesis or activity
JP2023536632A (ja) アルツハイマー病を処置するための組成物及び方法
BR0214293A (pt) Composto e métodos para tratar um paciente que tenha, ou de prevenir um paciente de adquirir, uma doença ou condição e para produzir um composto ou um sal ou éster farmaceuticamente aceitável do mesmo
WO2005082351A1 (ja) 神経変性疾患治療剤

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: PARA: INT. CL. C07D 277/00, A61P 25/28

Ipc: C07D 277/00 (2011.01), A61P 25/28 (2011.01)

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PEDIDO DE ACORDO COM O(S) ARTIGO(S) DA LPI

B06G Technical and formal requirements: other requirements [chapter 6.7 patent gazette]

Free format text: PARA QUE A PETICAO NPRJ 20130089481 DE 25/11/2013 POSSA SER ACEITA COMO PETICAO DE RECURSO, A TAXA DEVERA COMPLEMENTADA NO VALOR R$ 850,00 (OITOCENTOS E CINQUENTA REAIS) CONFORME TABELA DE RETRIBUICAO VIGENTE.

B12B Appeal against refusal [chapter 12.2 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B25D Requested change of name of applicant approved

Owner name: UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYS

B25G Requested change of headquarter approved

Owner name: UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYS

B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 16/04/2019, OBSERVADAS AS CONDICOES LEGAIS. (CO) 10 (DEZ) ANOS CONTADOS A PARTIR DE 16/04/2019, OBSERVADAS AS CONDICOES LEGAIS

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 24/08/2001 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 21A ANUIDADE.

B21H Decision of lapse of a patent or of a certificate of addition of invention cancelled [chapter 21.8 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 21.6 NA RPI NO 2684 DE 14/06/2022 POR TER SIDO INDEVIDA. UMA QUE O PRAZO DE VIGENCIA TERMINOU EM 08/2021.

B21A Patent or certificate of addition expired [chapter 21.1 patent gazette]

Free format text: PATENTE EXTINTA EM 24/08/2021